BridgeBio Pharma, Inc.
BBIO· Nasdaq
BBIOBridgeBio Pharma, Inc.
Filed Aug 11, 2020 · 10-Q · 42 days after period end · 0001564590-20-039358
| Metric | Q2 2020 | Q2 2019 |
|---|---|---|
| Net Income | -$136.21M | -$74.33M |
| EPS Diluted | -$1.03 | -$0.71 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BridgeBio Pharma, Inc. · CIK 1743881 · Engraved from SEC EDGAR
ended Jun 30, 2020 · filed Aug 11, 2020 · 42 d after period end
